BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 22.97 Million USD | 117.37% |
| 2022 | 10.67 Million USD | 138.72% |
| 2021 | 4.47 Million USD | 44.52% |
| 2020 | 3.09 Million USD | -56.05% |
| 2019 | 7.04 Million USD | -13.96% |
| 2018 | 8.18 Million USD | 63.36% |
| 2017 | 5 Million USD | 38.49% |
| 2016 | 3.61 Million USD | 47.86% |
| 2015 | 2.44 Million USD | 933.0% |
| 2014 | 236.79 Thousand USD | -1.5% |
| 2013 | 240.39 Thousand USD | -72.1% |
| 2012 | 861.63 Thousand USD | -45.44% |
| 2011 | 1.57 Million USD | 11.45% |
| 2010 | 1.41 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 35.01 Million USD | 158.1% |
| 2024 Q2 | 61.92 Million USD | 76.68% |
| 2023 FY | 22.97 Million USD | 115.22% |
| 2023 Q2 | 3.27 Million USD | 59.06% |
| 2023 Q4 | 13.56 Million USD | 391.24% |
| 2023 Q3 | 2.76 Million USD | -15.76% |
| 2023 Q1 | 2.06 Million USD | -52.2% |
| 2022 Q3 | 1.68 Million USD | 33.67% |
| 2022 FY | 10.67 Million USD | 138.72% |
| 2022 Q4 | 4.31 Million USD | 156.3% |
| 2022 Q1 | 3.18 Million USD | 211.94% |
| 2022 Q2 | 1.25 Million USD | -60.45% |
| 2021 FY | 4.47 Million USD | 44.52% |
| 2021 Q4 | 1.02 Million USD | -19.49% |
| 2021 Q1 | 1.07 Million USD | -1.12% |
| 2021 Q2 | 605.23 Thousand USD | -43.92% |
| 2021 Q3 | 1.26 Million USD | 109.38% |
| 2020 Q1 | 601.18 Thousand USD | -21.69% |
| 2020 Q3 | 800.06 Thousand USD | 33.03% |
| 2020 Q4 | 1.09 Million USD | 36.42% |
| 2020 FY | 3.09 Million USD | -56.05% |
| 2020 Q2 | 601.43 Thousand USD | 0.04% |
| 2019 Q1 | 2.53 Million USD | 0.0% |
| 2019 FY | 7.04 Million USD | -13.96% |
| 2019 Q4 | 767.65 Thousand USD | -50.01% |
| 2019 Q3 | 1.53 Million USD | -30.42% |
| 2019 Q2 | 2.2 Million USD | -12.77% |
| 2018 Q1 | 1.31 Million USD | 232.9% |
| 2018 FY | 8.18 Million USD | 63.36% |
| 2018 Q2 | 862.89 Thousand USD | -34.6% |
| 2017 Q3 | 1.62 Million USD | -2.84% |
| 2017 Q4 | 396.35 Thousand USD | -75.59% |
| 2017 FY | 5 Million USD | 38.49% |
| 2017 Q1 | 323.08 Thousand USD | -80.88% |
| 2017 Q2 | 1.67 Million USD | 417.23% |
| 2016 Q1 | 606.24 Thousand USD | -43.06% |
| 2016 Q2 | 2.31 Million USD | 281.06% |
| 2016 Q3 | 2.74 Million USD | 18.85% |
| 2016 Q4 | 1.68 Million USD | -38.46% |
| 2016 FY | 3.61 Million USD | 47.86% |
| 2015 Q3 | 376.04 Thousand USD | -49.2% |
| 2015 Q4 | 1.06 Million USD | 183.12% |
| 2015 Q2 | 740.2 Thousand USD | 183.74% |
| 2015 Q1 | 260.87 Thousand USD | 415.1% |
| 2015 FY | 2.44 Million USD | 933.0% |
| 2014 Q4 | 50.64 Thousand USD | -30.36% |
| 2014 Q2 | 112.95 Thousand USD | 41.49% |
| 2014 FY | 236.79 Thousand USD | -1.5% |
| 2014 Q1 | 79.83 Thousand USD | -47.24% |
| 2014 Q3 | 72.72 Thousand USD | -35.62% |
| 2013 Q3 | 10.89 Thousand USD | 0.0% |
| 2013 Q1 | 78.18 Thousand USD | 0.0% |
| 2013 FY | 240.39 Thousand USD | -72.1% |
| 2013 Q4 | 151.31 Thousand USD | 1289.38% |
| 2013 Q2 | - USD | -100.0% |
| 2012 FY | 861.63 Thousand USD | -45.44% |
| 2011 FY | 1.57 Million USD | 11.45% |
| 2010 FY | 1.41 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1620.404% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -355.664% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 22.259% |
| Nascent Biotech, Inc. | 2.22 Million USD | -930.316% |
| Rebus Holdings, Inc. | 664 Thousand USD | -3360.061% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 38.332% |
| Qrons Inc. | 643.67 Thousand USD | -3469.306% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -5797.538% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 60.002% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -5429.714% |
| Skye Bioscience, Inc. | 13.54 Million USD | -69.586% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 73.527% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -367.166% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -8678.189% |
| SQZ Biotechnologies Company | 85.61 Million USD | 73.166% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -687.824% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1429.717% |
| Mesoblast Limited | 5.9 Million USD | -289.271% |
| Marizyme, Inc. | 19.23 Million USD | -19.413% |
| Genus plc | 147.7 Million USD | 84.445% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -161.695% |
| Pharming Group N.V. | 225.49 Million USD | 89.811% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1021.43% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1612.563% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -175.51% |
| ContraFect Corporation | 56.88 Million USD | 59.615% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -421.127% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1453.662% |
| IMV Inc. | 37.7 Million USD | 39.074% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -723.364% |
| MultiCell Technologies, Inc. | 567.42 USD | -4048894.043% |
| ONE Bio Corp. | 6.44 Million USD | -256.536% |
| Accustem Sciences Inc. | 3.74 Million USD | -513.247% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 73.268% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -4218.88% |
| Q BioMed Inc. | 3.43 Million USD | -568.527% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 7.041% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -774.39% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2210.925% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 76.87% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1205.625% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -241.988% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1132.309% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 91999.208% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -43.501% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1151.968% |
| GB Sciences, Inc. | 1.42 Million USD | -1517.364% |
| Alpha Cognition Inc. | 9.7 Million USD | -136.717% |
| HST Global, Inc. | 140.9 Thousand USD | -16204.94% |
| CSL Limited | 3.44 Billion USD | 99.334% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1942.368% |
| Halberd Corporation | 74.84 Thousand USD | -30597.739% |
| Enzolytics Inc. | 2.17 Million USD | -954.128% |
| Agentix Corp. | 1.37 Million USD | -1574.846% |
| Resverlogix Corp. | 12.71 Million USD | -80.733% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -529.325% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.502% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2100.652% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -855.319% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1354.695% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -574.741% |
| AVAX Technologies, Inc. | 7.31 Million USD | -214.281% |
| Zenith Capital Corp. | 8.94 Million USD | -156.903% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.216% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -131779.927% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -835.716% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -13295.683% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1096.04% |
| Kadimastem Ltd | 2.41 Million USD | -853.267% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1065.031% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -111.418% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -12559.339% |
| LadRx Corporation | 3.81 Million USD | -502.73% |
| Cell Source, Inc. | 4.32 Million USD | -431.167% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2387.77% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2387.77% |
| NovAccess Global Inc. | 2.46 Million USD | -831.375% |
| Affymax, Inc. | 39.38 Million USD | 41.668% |
| Itoco Inc. | 919.14 Thousand USD | -2399.59% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -442.061% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1953.155% |
| Mobile Lads Corp. | 554.54 Thousand USD | -4042.993% |
| CytoDyn Inc. | 18.05 Million USD | -27.228% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -91182.141% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -10339.391% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1518.181% |
| SYBLEU INC | 160.87 Thousand USD | -14181.062% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1164.909% |
| International Stem Cell Corporation | 5.27 Million USD | -335.872% |
| Bioxytran, Inc. | 3.82 Million USD | -501.411% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -43543.482% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -112837.138% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 36.649% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1319.951% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3022.276% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -638.502% |
| Neutra Corp. | 243.82 Thousand USD | -9322.815% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -31.608% |
| PureTech Health plc | 144.59 Million USD | 84.111% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -12.128% |
| IXICO plc | 4.7 Million USD | -388.099% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -161.166% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 80.488% |
| CSL Limited | 3.89 Billion USD | 99.41% |
| Cellectis S.A. | 97.32 Million USD | 76.393% |